Your browser doesn't support javascript.
loading
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
Karuna, Shelly; Li, Shuying Sue; Grant, Shannon; Walsh, Stephen R; Frank, Ian; Casapia, Martin; Trahey, Meg; Hyrien, Ollivier; Fisher, Leigh; Miner, Maurine D; Randhawa, April K; Polakowski, Laura; Kublin, James G; Corey, Lawrence; Montefiori, David.
Afiliación
  • Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Grant S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Walsh SR; Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Frank I; Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Casapia M; Asociación Civil Selva Amazónica, Iquitos, Peru.
  • Trahey M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Hyrien O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Fisher L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Polakowski L; Division of AIDS, NIAID, NIH, Bethesda, Maryland, United States of America.
  • Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Montefiori D; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
PLoS Med ; 18(12): e1003868, 2021 12.
Article en En | MEDLINE | ID: mdl-34871308
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / America do sul / Peru Idioma: En Revista: PLoS Med Asunto de la revista: MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / America do sul / Peru Idioma: En Revista: PLoS Med Asunto de la revista: MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos